Seeking Alpha
Full index of posts »
Posts by Ticker
Latest Comments
-
clawmann on What Katrina Was to FEMA, Swine Flu Deaths Are to FDA - Buy BioCryst And, today, after this was published FDA gave B...
-
lrrplrrpalpha on What Katrina Was to FEMA, Swine Flu Deaths Are to FDA - Buy BioCryst What is the FDA waiting for? Increasing numbers...
-
shadowhunter on What Katrina Was to FEMA, Swine Flu Deaths Are to FDA - Buy BioCryst jq1234, if you opine about the article negative...
-
jq1234 on Buy The Obesity Drug Basket: ARNA, OREX, VVUS "there was good patient compliance with on...
-
jq1234 on What Katrina Was to FEMA, Swine Flu Deaths Are to FDA - Buy BioCryst Most ridiculous article on SA.
Posts by Themes
BioCryst,
biotech,
Biotech,
cancer,
CDC,
coincident indicators,
Contrave,
diet drugs,
Dow Jones,
Economy,
FDA,
H1N1,
healthcare,
HHS,
ICU,
influenza,
lorcaserin,
Market,
Nasdaq,
obesity,
pandemic,
peramivir,
prostate cancer,
Provenge,
Qnexa,
recession,
recovery,
Relenza,
S P,
stock market,
swine flu,
Tamiflu,
weight loss
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.












What Katrina Was to FEMA, Swine Flu Deaths Are to FDA - Buy BioCryst
Buy The Obesity Drug Basket: ARNA, OREX, VVUS
OMG - It's A V-Shaped Recovery!
The Recession Is Over
It's deep summer at last, and that means lower trading volume and an easier time manipulating the market for those so inclined. The reasons given for the recent weakness – worries about the timing and pace of the economic recovery – didn't make sense to me. I wrote about the lagging indicators in http://seekingalpha.com/article/143237-bad-news-they-re-just-lagging-indicators on June 15 and said don't let the laggers and those who quote them fool you, the recession is over. Now I've taken a look at the leading indicators, as you'll see below, the story is the same:
More »The Recession Is Over
The recession is over.
More »A Biotech Triple Play: Dendreon (DNDN) to BioCryst (BCRX) to Arena (ARNA)
There's only one thing better than catching a big stock market winner like Dendreon, and that's letting your profits ride on two or three winners in a row. Even though not one of the seven Wall Street analysts following Dendreon had a buy on the stock before the recent announcement that the final Phase III trial of the company's Provenge prostate cancer drug was a clear success, we had it listed as a Top Buy for many months and subscribers rode it from under $5 to over $20. I've recently asked them to sell some Dendreon and buy a position in BioCryst before a pending announcement, planning to sell the BioCryst this summer to buy Arena Pharmaceuticals before their September announcement of the second Phase III lorcaserin obesity drug trials.
More »